Raquel Oliva Alencar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deoxyguanosine | 7 | 2004 | 92 | 0.570 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2016 | 329 | 0.420 |
Why?
|
| Hemangioma | 1 | 2016 | 727 | 0.370 |
Why?
|
| Contrast Media | 6 | 2016 | 5298 | 0.330 |
Why?
|
| Gastrointestinal Tract | 3 | 2012 | 830 | 0.310 |
Why?
|
| Iohexol | 3 | 2016 | 204 | 0.270 |
Why?
|
| Barium Sulfate | 2 | 2012 | 180 | 0.230 |
Why?
|
| Glutathione | 7 | 2004 | 579 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2004 | 1355 | 0.210 |
Why?
|
| Cryosurgery | 2 | 2014 | 475 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2016 | 20500 | 0.200 |
Why?
|
| beta 2-Microglobulin | 3 | 2000 | 328 | 0.190 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2023 | 148 | 0.190 |
Why?
|
| Kidney Neoplasms | 3 | 2023 | 4312 | 0.180 |
Why?
|
| HLA Antigens | 5 | 1993 | 1368 | 0.160 |
Why?
|
| Oxidative Stress | 4 | 2004 | 3100 | 0.160 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 875 | 0.150 |
Why?
|
| Antioxidants | 4 | 2004 | 1662 | 0.140 |
Why?
|
| Water | 1 | 2012 | 1402 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2023 | 3217 | 0.130 |
Why?
|
| Rifamycins | 2 | 1995 | 26 | 0.120 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2006 | 221 | 0.120 |
Why?
|
| DNA Damage | 4 | 2001 | 2439 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 785 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2004 | 285 | 0.110 |
Why?
|
| Fibrosarcoma | 2 | 2004 | 308 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 36285 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4313 | 0.100 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2003 | 183 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2014 | 187 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 2 | 2012 | 1185 | 0.100 |
Why?
|
| Deoxyribose | 1 | 2001 | 7 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2004 | 585 | 0.100 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 568 | 0.090 |
Why?
|
| Catalase | 4 | 2003 | 216 | 0.090 |
Why?
|
| Reactive Oxygen Species | 3 | 2004 | 2129 | 0.090 |
Why?
|
| Fatty Liver | 1 | 2006 | 777 | 0.080 |
Why?
|
| Biopsy | 2 | 2023 | 6768 | 0.080 |
Why?
|
| Malondialdehyde | 3 | 2004 | 111 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2292 | 0.080 |
Why?
|
| Superoxide Dismutase | 4 | 2003 | 593 | 0.080 |
Why?
|
| Genes, ras | 2 | 1992 | 654 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 2001 | 928 | 0.080 |
Why?
|
| Copper | 3 | 2001 | 366 | 0.080 |
Why?
|
| Homocysteine | 1 | 2001 | 638 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2006 | 1296 | 0.070 |
Why?
|
| Glutathione Peroxidase | 3 | 2003 | 255 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 3339 | 0.070 |
Why?
|
| Cysteine | 1 | 2001 | 893 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 2 | 1990 | 514 | 0.060 |
Why?
|
| Genes, MHC Class I | 3 | 1991 | 240 | 0.060 |
Why?
|
| Papillomaviridae | 2 | 1993 | 1121 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2004 | 12760 | 0.060 |
Why?
|
| Point Mutation | 1 | 2000 | 1593 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2007 | 1121 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2004 | 6127 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 3024 | 0.050 |
Why?
|
| tert-Butylhydroperoxide | 2 | 2004 | 11 | 0.050 |
Why?
|
| Aged | 13 | 2016 | 168217 | 0.050 |
Why?
|
| Condylomata Acuminata | 1 | 1993 | 75 | 0.050 |
Why?
|
| Suspensions | 1 | 2012 | 66 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 1998 | 1997 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 58681 | 0.050 |
Why?
|
| Middle Aged | 14 | 2016 | 219560 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2000 | 2666 | 0.050 |
Why?
|
| Melanoma | 4 | 2000 | 5691 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 20052 | 0.050 |
Why?
|
| Wisconsin | 1 | 2011 | 122 | 0.050 |
Why?
|
| Male | 18 | 2023 | 358742 | 0.050 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1991 | 86 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 2850 | 0.050 |
Why?
|
| Colorectal Neoplasms | 4 | 2000 | 6852 | 0.040 |
Why?
|
| HLA-DR Antigens | 2 | 1992 | 630 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1993 | 438 | 0.040 |
Why?
|
| Genes, myc | 1 | 1991 | 391 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 3425 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2023 | 80170 | 0.040 |
Why?
|
| Adenocarcinoma | 3 | 2007 | 6313 | 0.040 |
Why?
|
| HLA-D Antigens | 1 | 1989 | 134 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14641 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 1993 | 583 | 0.040 |
Why?
|
| Stomach Neoplasms | 2 | 1989 | 1422 | 0.040 |
Why?
|
| Female | 17 | 2016 | 390316 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 2004 | 0.040 |
Why?
|
| DNA, Viral | 2 | 1993 | 2194 | 0.040 |
Why?
|
| Codon | 1 | 1990 | 602 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2000 | 330 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2007 | 4023 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 9468 | 0.040 |
Why?
|
| Stomach | 1 | 2012 | 694 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5649 | 0.040 |
Why?
|
| Pelvis | 1 | 2012 | 743 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2634 | 0.040 |
Why?
|
| Thiourea | 2 | 2001 | 68 | 0.040 |
Why?
|
| Humans | 27 | 2023 | 758381 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 1993 | 796 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 11894 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2007 | 1648 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1992 | 559 | 0.030 |
Why?
|
| Liver | 2 | 2000 | 7502 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 1989 | 600 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2011 | 694 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 2600 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2012 | 1207 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1998 | 617 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 1993 | 977 | 0.030 |
Why?
|
| Adult | 10 | 2014 | 219916 | 0.030 |
Why?
|
| Gene Amplification | 3 | 1997 | 1085 | 0.030 |
Why?
|
| DNA | 2 | 2003 | 7199 | 0.030 |
Why?
|
| Base Sequence | 5 | 1999 | 12436 | 0.030 |
Why?
|
| BALB 3T3 Cells | 1 | 2004 | 10 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2000 | 1844 | 0.030 |
Why?
|
| Blotting, Southern | 3 | 1989 | 777 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2007 | 532 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6233 | 0.030 |
Why?
|
| Glutathione Disulfide | 1 | 2003 | 33 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 1993 | 8506 | 0.030 |
Why?
|
| Thymus Gland | 2 | 2001 | 1244 | 0.030 |
Why?
|
| Molecular Sequence Data | 5 | 1999 | 17617 | 0.030 |
Why?
|
| Hypertension | 1 | 2003 | 8503 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2001 | 2222 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2005 | 500 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2009 | 2359 | 0.030 |
Why?
|
| Cattle | 2 | 2001 | 3846 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1628 | 0.030 |
Why?
|
| DNA Probes, HPV | 2 | 1993 | 21 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 5787 | 0.030 |
Why?
|
| Methylcholanthrene | 1 | 2001 | 31 | 0.020 |
Why?
|
| Aging | 1 | 2000 | 8651 | 0.020 |
Why?
|
| Lymphatic Metastasis | 4 | 1990 | 2943 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 1046 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2001 | 217 | 0.020 |
Why?
|
| Oxygen Consumption | 2 | 2001 | 1846 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6457 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2001 | 294 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2001 | 310 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4901 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1993 | 2016 | 0.020 |
Why?
|
| Mutation | 2 | 1999 | 29915 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2005 | 1159 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2001 | 1084 | 0.020 |
Why?
|
| DNA Primers | 1 | 2004 | 2816 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2012 | 54136 | 0.020 |
Why?
|
| Skin Neoplasms | 3 | 2000 | 5797 | 0.020 |
Why?
|
| Gadolinium | 1 | 2003 | 959 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1990 | 2523 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 1993 | 1705 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 869 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 856 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 1993 | 6068 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2001 | 655 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2000 | 659 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2023 | 12951 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 1997 | 74 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4567 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1997 | 246 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3609 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11709 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 1997 | 346 | 0.020 |
Why?
|
| Spain | 1 | 1997 | 488 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1997 | 385 | 0.020 |
Why?
|
| Free Radicals | 1 | 1995 | 238 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1997 | 635 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2000 | 2673 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1997 | 367 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1997 | 712 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8946 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 2 | 1993 | 3617 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 15646 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 4087 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2007 | 466 | 0.010 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1993 | 45 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9273 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 21273 | 0.010 |
Why?
|
| Fetus | 1 | 2000 | 1860 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 2472 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1997 | 1492 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1991 | 5246 | 0.010 |
Why?
|
| Lung | 1 | 1991 | 9985 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 6209 | 0.010 |
Why?
|
| Animals | 5 | 2004 | 167777 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 1745 | 0.010 |
Why?
|
| Rats | 2 | 2000 | 23681 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 5864 | 0.010 |
Why?
|
| Neoplasms | 1 | 2000 | 22030 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1997 | 2608 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 29558 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 4048 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7590 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 2797 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 416 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 13276 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23883 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 39873 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1998 | 74 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 1304 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 4106 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 1990 | 328 | 0.010 |
Why?
|
| HLA-B Antigens | 1 | 1989 | 331 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15225 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 8453 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1990 | 1647 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2000 | 2276 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 13468 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 6821 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1991 | 13245 | 0.010 |
Why?
|
| Ethanol | 1 | 1993 | 1325 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 6955 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2821 | 0.010 |
Why?
|
| Mice | 2 | 2004 | 81107 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 58808 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 2882 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8530 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1997 | 4485 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 73806 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1988 | 2470 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1990 | 2905 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 11152 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 16534 | 0.010 |
Why?
|
| Pregnancy | 1 | 2000 | 29742 | 0.000 |
Why?
|
| Peptides | 1 | 1998 | 4341 | 0.000 |
Why?
|
| Cell Line | 1 | 1990 | 15594 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1992 | 11471 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1989 | 9160 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2007 | 64379 | 0.000 |
Why?
|